Diversified Trust Co Sells 30,519 Shares of Pfizer, Inc. (PFE)
Diversified Trust Co reduced its stake in shares of Pfizer, Inc. (NYSE:PFE) by 27.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 79,895 shares of the biopharmaceutical company’s stock after selling 30,519 shares during the period. Diversified Trust Co’s holdings in Pfizer were worth $2,733,000 at the end of the most recent reporting period.
Several other hedge funds also recently modified their holdings of the stock. Norges Bank acquired a new position in Pfizer during the fourth quarter valued at $1,896,890,000. State Street Corp raised its stake in shares of Pfizer by 3.5% in the fourth quarter. State Street Corp now owns 320,794,199 shares of the biopharmaceutical company’s stock valued at $10,419,393,000 after buying an additional 10,838,463 shares in the last quarter. Asset Management One Co. Ltd. raised its stake in shares of Pfizer by 618.4% in the fourth quarter. Asset Management One Co. Ltd. now owns 11,094,592 shares of the biopharmaceutical company’s stock valued at $360,362,000 after buying an additional 9,550,335 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main purchased a new stake in shares of Pfizer during the fourth quarter valued at approximately $289,666,000. Finally, Appaloosa LP purchased a new stake in shares of Pfizer during the fourth quarter valued at approximately $156,229,000. Institutional investors and hedge funds own 69.95% of the company’s stock.
Pfizer, Inc. (PFE) traded up 0.33% during mid-day trading on Friday, reaching $33.54. The company had a trading volume of 16,060,060 shares. The stock has a market capitalization of $200.16 billion, a price-to-earnings ratio of 24.54 and a beta of 1.00. Pfizer, Inc. has a 52-week low of $29.83 and a 52-week high of $35.95. The company’s 50 day moving average is $33.38 and its 200 day moving average is $33.25.
Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.65 by $0.02. The business had revenue of $12.90 billion for the quarter, compared to the consensus estimate of $13.08 billion. Pfizer had a return on equity of 24.11% and a net margin of 15.84%. Pfizer’s revenue was down 1.9% compared to the same quarter last year. During the same period in the previous year, the business earned $0.64 EPS. Equities analysts predict that Pfizer, Inc. will post $2.56 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, September 1st. Stockholders of record on Friday, August 4th will be issued a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 3.83%. The ex-dividend date is Wednesday, August 2nd. Pfizer’s payout ratio is currently 94.12%.
TRADEMARK VIOLATION NOTICE: “Diversified Trust Co Sells 30,519 Shares of Pfizer, Inc. (PFE)” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another publication, it was illegally copied and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/08/04/diversified-trust-co-sells-30519-shares-of-pfizer-inc-pfe-updated-updated-updated.html.
Several brokerages have commented on PFE. Morgan Stanley restated a “neutral” rating and set a $38.00 price target on shares of Pfizer in a research note on Thursday, April 6th. BidaskClub upgraded Pfizer from a “strong sell” rating to a “sell” rating in a research note on Friday, June 23rd. Jefferies Group LLC reiterated a “neutral” rating and issued a $35.00 target price (up previously from $34.00) on shares of Pfizer in a research note on Thursday, April 13th. BMO Capital Markets reiterated a “hold” rating and issued a $33.00 target price on shares of Pfizer in a research note on Thursday, April 27th. Finally, Sanford C. Bernstein restated a “buy” rating and set a $35.00 price objective on shares of Pfizer in a research note on Monday, April 24th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $37.77.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.